Showing 5521-5530 of 5771 results for "".
- BlephEx Names Fred Ellis CEOhttps://modernod.com/news/blephex-names-fred-ellis-ceo/2480014/BlephEx has announced that Fred Ellis is the company’s new CEO. Mr. Ellis comes to BlephEx with 29+ years of experience with Alcon-Novartis. While there, he held numerous positions of increased responsibility overseeing a wide range of commercial assignments. He is recognized for having exception
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi
- Complications After Intravitreal Injection Aggravatehttps://modernod.com/news/complications-after-intravitreal-injection-aggravate/2480023/Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and best practices at the upcoming American Society of Retina Specialists (ASRS) 2018 Annual Meeting, according to a
- Zeiss Names New Chief Financial Officerhttps://modernod.com/news/zeiss-names-news-chief-financial-officer/2480025/Christian Müller, PhD, will become Chief Financial Officer of Carl Zeiss AG, succeeding Thomas Spitzenpfeil who, as previously announced, will leave the company. Dr. Müller has been CFO of the Zeiss subsidiary Carl Zeiss Meditec AG since 2009. He joined the Zeiss Group in 2002 as head of Corporat
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- Iridex Reaches Milestone of 1000th Cyclo G6 System Shippedhttps://modernod.com/news/iridex-reaches-milestone-of-1000th-cyclo-g6-system-shipped/2480033/Iridex announced that in the second quarter of 2018 it shipped the 1,000th unit of its »Cyclo G6 Laser System, which utilizes the company’s propri
- Allergan Launches New Refresh Repair Lubricant Eye Dropshttps://modernod.com/news/allergan-launches-new-refresh-repair-lubricant-eye-drops/2480034/Allergan announced the launch of a new over-the-counter artificial tear formulation, Refresh Repair Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants, Refresh Repair
- Takeda Receives Clearance from the FTC for the Proposed Acquisition of Shirehttps://modernod.com/news/takeda-receives-clearance-from-the-ftc-for-the-proposed-acquisition-of-shire/2480035/Takeda Pharmaceutical announced that it has received unconditional clearance from the United States Federal Trade Commission (FTC) for the proposed acquisition of Shire announced on May 8, 2018. Takeda’s proposed acquisition of Shire is valued at around 46 billion pounds ($60.9 billion).
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.